AIRDOC-B (02251) recommends appointing Wu Haoran as an independent non-executive director.
Eagle Eye Technology-B (02251) has announced that at the meeting held on September 20, 2024, the board of directors decided...
AIRDOC-B (02251) Announcement: At the meeting held on September 20, 2024, the board of directors decided (i) to propose the appointment of Mr. Wu Haoran as an independent non-executive director of the second board of directors at the upcoming special shareholders' meeting for shareholders' consideration and approval, and (ii) to appoint Mr. Wu as the chairman of the audit committee and a member of the remuneration and assessment committee and the strategic committee (subject to Mr. Wu's appointment as an independent non-executive director being approved by shareholders). The appointment of Mr. Wu as the chairman of the audit committee, a member of the remuneration and assessment committee, and the strategic committee will take effect after being approved by shareholders at the special shareholders' meeting for his appointment as an independent non-executive director.
Related Articles

Shandong Xinhua (00719): Xinda Pharmaceuticals has obtained the registration certificate for ibuprofen granules medication.
REGO INTERACT (02422) issued a profit warning, with the expected net loss attributable to owners of the company in 2025 not less than 68.4 million yuan, an increase of 74.0% year-on-year.

LAOPU GOLD (06181) released its annual performance, with a profit attributable to shareholders of 4.868 billion yuan, an increase of 230.5% year-on-year.
Shandong Xinhua (00719): Xinda Pharmaceuticals has obtained the registration certificate for ibuprofen granules medication.

REGO INTERACT (02422) issued a profit warning, with the expected net loss attributable to owners of the company in 2025 not less than 68.4 million yuan, an increase of 74.0% year-on-year.
LAOPU GOLD (06181) released its annual performance, with a profit attributable to shareholders of 4.868 billion yuan, an increase of 230.5% year-on-year.






